卵巢癌当前及未来的免疫治疗方法
Current and future immunotherapy approaches in ovarian cancer.
作者信息
Demircan Nazım Can, Boussios Stergios, Tasci Tolga, Öztürk Mehmet Akif
机构信息
Division of Medical Oncology, Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey.
Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK.
出版信息
Ann Transl Med. 2020 Dec;8(24):1714. doi: 10.21037/atm-20-4499.
Abstract
Ovarian cancer (OC) is the major cause of gynecologic cancer deaths and relapse is common despite advances in surgery and systemic chemotherapy. Therefore, novel treatments are required to improve long-term outcomes of the disease. Efficacy of immunotherapy was demonstrated in many tumors and it has been since incorporated into clinical practice for them. Although early data form preclinical studies imply that OC has an immunogenic microenvironment, immune checkpoint inhibitors (ICIs) did not produce favorable results in clinical trials to date. This review will highlight data from clinical studies regarding immunotherapy in OC and its combination with other agents as well as immunologic prospects which could strengthen the therapeutic armament against the disease in the future.
摘要
卵巢癌（OC）是妇科癌症死亡的主要原因，尽管手术和全身化疗取得了进展，但复发仍很常见。因此，需要新的治疗方法来改善该疾病的长期预后。免疫疗法在许多肿瘤中都显示出疗效，并且此后已被纳入这些肿瘤的临床实践。尽管临床前研究的早期数据表明OC具有免疫原性微环境，但免疫检查点抑制剂（ICI）迄今为止在临床试验中并未产生令人满意的结果。本综述将重点介绍关于OC免疫疗法及其与其他药物联合应用的临床研究数据，以及未来可能加强针对该疾病治疗手段的免疫学前景。
相似文献
1
Current and future immunotherapy approaches in ovarian cancer.卵巢癌当前及未来的免疫治疗方法
Ann Transl Med. 2020 Dec;8(24):1714. doi: 10.21037/atm-20-4499.
2
Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?免疫疗法与放射疗法联合治疗妇科肿瘤的临床试验：是否具有协同作用？
Gynecol Oncol. 2019 Jul;154(1):236-245. doi: 10.1016/j.ygyno.2019.03.255. Epub 2019 Apr 14.
3
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.免疫检查点抑制剂在卵巢癌治疗中的新作用。
Expert Opin Emerg Drugs. 2020 Dec;25(4):445-453. doi: 10.1080/14728214.2020.1836155. Epub 2020 Oct 20.
4
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.免疫检查点抑制剂的未来：聚焦肿瘤免疫微环境。
Ann Transl Med. 2020 Sep;8(17):1095. doi: 10.21037/atm-20-3735.
5
Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.遗传和表观遗传策略在卵巢癌免疫治疗中的应用。
Expert Opin Biol Ther. 2019 Jun;19(6):547-560. doi: 10.1080/14712598.2019.1602605. Epub 2019 Apr 15.
6
Current status of cancer immunotherapy for gynecologic malignancies.妇科恶性肿瘤的癌症免疫治疗现状。
Jpn J Clin Oncol. 2021 Feb 8;51(2):167-172. doi: 10.1093/jjco/hyaa214.
7
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).非小细胞肺癌（NSCLC）中的免疫检查点抑制剂（ICIs）。
J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173.
8
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives.上皮性卵巢癌中的免疫检查点抑制剂：疗效与未来展望概述
Diagnostics (Basel). 2020 Mar 7;10(3):146. doi: 10.3390/diagnostics10030146.
9
Immunotherapy for ovarian cancer: recent advances and perspectives.卵巢癌的免疫疗法：最新进展与展望
Curr Opin Oncol. 2014 Sep;26(5):492-500. doi: 10.1097/CCO.0000000000000111.
10
Ovarian Cancer Immunotherapy: Turning up the Heat.卵巢癌免疫治疗：点燃希望。
Int J Mol Sci. 2019 Jun 15;20(12):2927. doi: 10.3390/ijms20122927.
引用本文的文献
1
Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives.免疫疗法在卵巢癌中的作用：进展、挑战及未来展望
Cancer Treat Res. 2025;129:187-220. doi: 10.1007/978-3-031-97242-3_10.
2
Worldwide Research Trends on the Immunotherapy-Based Treatment of Ovarian Cancers: A Bibliometric and Visual Analysis.基于免疫疗法的卵巢癌治疗的全球研究趋势：文献计量与可视化分析
J Multidiscip Healthc. 2025 Jul 25;18:4197-4217. doi: 10.2147/JMDH.S526280. eCollection 2025.
3
Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis.免疫肿瘤学中的新兴概念：来自自然语言处理驱动的共现分析的见解
ACS Omega. 2025 Jun 27;10(27):28587-28614. doi: 10.1021/acsomega.5c00693. eCollection 2025 Jul 15.
4
Treatment of ovarian cancer: From the past to the new era (Review).卵巢癌的治疗：从过去到新时代（综述）
Oncol Lett. 2025 Jun 3;30(2):384. doi: 10.3892/ol.2025.15130. eCollection 2025 Aug.
5
Functional heterogeneity and clinical implications of CD4+ T cell subtypes in high-grade serous ovarian carcinoma.高级别浆液性卵巢癌中CD4+ T细胞亚群的功能异质性及临床意义
World J Clin Oncol. 2025 May 24;16(5):104138. doi: 10.5306/wjco.v16.i5.104138.
6
Construction of self-driving anti-αFR CAR-engineered NK cells based on IFN-γ and TNF-α synergistically induced high expression of CXCL10.基于 IFN-γ 和 TNF-α 协同诱导高表达 CXCL10，构建了自我驾驶的抗-αFR CAR 工程化 NK 细胞。
Neoplasia. 2024 Dec;58:101065. doi: 10.1016/j.neo.2024.101065. Epub 2024 Oct 3.
7
Ecological and evolutionary dynamics to design and improve ovarian cancer treatment.设计和改进卵巢癌治疗的生态和进化动态。
Clin Transl Med. 2024 Sep;14(9):e70012. doi: 10.1002/ctm2.70012.
8
Immune pathway through endometriosis to ovarian cancer.通过子宫内膜异位症发展为卵巢癌的免疫途径。
World J Clin Oncol. 2024 Apr 24;15(4):496-522. doi: 10.5306/wjco.v15.i4.496.
9
Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.BTLA 和 PD-1 的双重抑制可以增强紫杉醇对腹腔内播散肿瘤的治疗效果。
J Immunother Cancer. 2023 Jul;11(7). doi: 10.1136/jitc-2023-006694.
10
ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer.ANKRD22 是逆转卵巢癌中 PMN-MDSC 的免疫抑制作用的潜在新靶点。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005527.
本文引用的文献
1
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.随机 II 期试验：纳武利尤单抗对比纳武利尤单抗联合伊匹单抗用于复发性或持续性卵巢癌：NRG 肿瘤学研究。
J Clin Oncol. 2020 Jun 1;38(16):1814-1823. doi: 10.1200/JCO.19.02059. Epub 2020 Apr 10.
2
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.多聚（ADP-核糖）聚合酶抑制剂：奥拉帕利在卵巢癌及其他领域的应用。
Drugs R D. 2020 Jun;20(2):55-73. doi: 10.1007/s40268-020-00301-8.
3
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.尼拉帕利治疗卵巢癌：一种新的合成致死治疗方法。
Invest New Drugs. 2020 Feb;38(1):181-193. doi: 10.1007/s10637-019-00867-4. Epub 2019 Oct 24.
4
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.评估纳武利尤单抗联合贝伐珠单抗治疗复发性卵巢癌：一项 2 期临床试验。
JAMA Oncol. 2019 Dec 1;5(12):1731-1738. doi: 10.1001/jamaoncol.2019.3343.
5
Prospects for combining immune checkpoint blockade with PARP inhibition.免疫检查点阻断与 PARP 抑制联合的前景。
J Hematol Oncol. 2019 Sep 14;12(1):98. doi: 10.1186/s13045-019-0784-8.
6
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.聚（ADP-核糖）聚合酶（PARP）抑制剂联合策略治疗卵巢癌：文献综述
Diagnostics (Basel). 2019 Aug 1;9(3):87. doi: 10.3390/diagnostics9030087.
7
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.在一项晚期/复发性卵巢和子宫癌的 I 期研究中评估阿替利珠单抗的安全性、临床活性和生物标志物。
Gynecol Oncol. 2019 Aug;154(2):314-322. doi: 10.1016/j.ygyno.2019.05.021. Epub 2019 Jun 14.
8
PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".PARP抑制剂在卵巢癌中的应用：通往“伊萨卡”之路
Diagnostics (Basel). 2019 May 18;9(2):55. doi: 10.3390/diagnostics9020055.
9
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.帕博利珠单抗治疗晚期复发性卵巢癌患者的抗肿瘤活性和安全性：来自 II 期 KEYNOTE-100 研究的结果。
Ann Oncol. 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135.
10
PARP Inhibitor Efficacy Depends on CD8 T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.聚腺苷二磷酸核糖聚合酶抑制剂的疗效取决于 BRCA 缺陷型三阴性乳腺癌模型中通过肿瘤内 STING 通路激活募集 CD8 T 细胞。
Cancer Discov. 2019 Jun;9(6):722-737. doi: 10.1158/2159-8290.CD-18-1218. Epub 2019 Apr 23.
Zotero 插件